Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients

NCT06931080 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

630

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: EB-1020 (Centanafadine) 164.4 mg
DRUG: EB-1020 (Centanafadine) 328.8 mg
DRUG: Placebo

Sponsor

Otsuka Pharmaceutical Co., Ltd.